Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
CFT8634 | PROTAC BRD9 Degrader | MedChemExpress
CFT8634 | TargetMol
CFT8634 | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
CFT8634 CAS#: 2704617-96-7
好消息|2022 年 3 月 9 日|C4 Therapeutics 宣布 FDA 将 CFT8634 指定为用于治疗软组织肉瘤的孤儿药 - 知乎
美国APExBIO中文官网 - CFT8634
CFT8634 是一种用于治疗滑膜肉瘤和 SMARCB1缺失 肿瘤的口服生物可利用的 BiDAC ™降解剂 - 知乎
CFT-8634 (CFT8634) | BRD9 PROTAC | Probechem Biochemicals
Medchemexpress - 🧬Molecule of the Moment | #CFT8634 is an orally ...
AACR上首次公布结构的10款疗法
杰克说药 | 如何设计你的专有PROTACs？_药物_蛋白_沙利
Frontiers | E3 ligase ligand optimization of Clinical PROTACs
Ten Ways Degraders Differentiate from Traditional Small Molecules
2022 AACR总结：最值得关注的小分子药物研发方向TOP10 2022年美国癌症研究协会（AACR）已然落幕，作为全球历史最悠久、规模最大 ...
蛋白降解剂新篇章：2023年6大创新靶点临床进展深度解析（上）_腾讯新闻
FHD-609 | BRD9 PROTAC | Probechem Biochemicals
C4 Therapeutics：BiDAC降解剂 CFT8634已完成1/2 期临床试验中第一位患者给药|癌症|患者|降解|治疗|药物|-健康界
医药魔方
Discovery of CFT8634, a Potent, Selective, and Orally Bioavailable ...
BRD9 ligand-5 | Ligand for Target Protein for PROTAC | MedChemExpress
CFT8634, a Clinical Stage BRD9 Bi DAC™ Degrader, Is Active in a Subset ...
Frontiers | Emerging targeted and cellular therapies in the treatment ...
Abstract 6046: CFT8634, a BRD9 BiDAC™ degrader, is active in a subset ...
Abstract ND09: The discovery and characterization of CFT8634: A potent ...
BRD9 ligand-5 | TargetMol
Overview of epigenetic degraders based on PROTAC, molecular glue, and ...
Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative ...
Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious ...
The BRD9 degrader, QA-68-ZU81, shows increased potency and selectivity ...
Gustavo J. Gutierrez, PhD on LinkedIn: BRD9 orally bioavailable ...
PROTAC BRD9 Degrader-4, 2633632-34-3 | BroadPharm
BRD9 Degrader-3 | TargetMol
BRD9 Degrader-4 | TargetMol
(CFT-8634)-药物靶点：BRD9_在研适应症：实体瘤，滑膜肉瘤_专利_临床_研发
【PROTAC BRD9 Degrader-4】PROTAC BRD9 Degrader-4 CAS号:2633632-34-3【结构式 性质 ...
Naphthiridinone degrader 6 (dBRD9) offers improved biochemical and ...
Discovery of a Highly Potent and Selective BRD9 PROTAC Degrader Based ...
(PDF) BRD9 degraders as chemosensitizers in acute leukemia and multiple ...
BRD9 Degrader-4 | C30H40N4O4 | CID 170620619 - PubChem
BRD9 Bifunctional Degraders for Treating Cancer | ACS Medicinal ...
医药魔方 | 降解剂“竞技”AACR - 知乎
Jmolで見るトピックス分子（16-5）
Degraders | BroadPhar | BroadPharm
Preclinical evaluation of proteolytic targeting of LCK as a therapeutic ...
Design and characterization of thienopyridinone BRD9-targeted ...
LOGO
Design and synthesis of potent and selective inhibitors of BRD7 and ...
Cereblon Inhibitor, Degrader, Gene | MedChemExpress
PROTAC - PROTAC - Signaling Pathways
CRBN ligand-11 | TargetMol
RCSB PDB - 9F1M: First bromodomain of BRD4 in complex with ISOX-DUAL ...
RCSB PDB - 9F1J: First bromodomain of BRD4 in complex with ISOX-DUAL ...
Epigenetic Reader Domain - Chromatin/Epigenetics - Signaling Pathways
药渡Cyber解析作为BRD9的强效、选择性和口服有效的PROTAC降解剂CW-3308的发现 - 知乎
Linkers for Linkerology - Enamine
RCSB PDB - 9F1L: First bromodomain of BRD4 in complex with ISOX-DUAL ...
PROTAC四大龙头公司系列：C4 Therapeutics - 推荐阅读 - PharmaTEC制药网
Cell Rep Med丨谢琦等团队合作发现靶向BRD9可增强胶质母细胞瘤溶瘤病毒疗法疗效医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
cccc-20221231
Letters from Drug Hunters #1 – Apr. 2022
Enzyme-derived click formation of heterobifunctional degraders of BRD4 ...
C4 Therapeutics (@C4Therapeutics) / Twitter
A direct high-throughput protein quantification strategy facilitates ...
Aberrant activation of m6A demethylase FTO renders HIF2αlow/− clear ...
C4 Therapeutics (CCCC), 로슈는 왜 오다 말았을까? : 네이버 블로그
drug hunter on Twitter: "And that's it for AACR New Drugs Session! All ...
Temporal and Spatial Characterization of CUL3KLHL20-driven Targeted ...
Structure-guided design and characterization of Brd4-selective degrader ...
Clinical trials exploring anti BRAF-EGFR combinations in mCRC ...
(a) Structures of ARV-825 and MZ1, BRD4 protein degraders based on BET ...
Evaluation of the Small-molecule BRD4 Degrader CFT-2718 in Small-cell ...
Identification of Selective BRD9 Inhibitor via Integrated Computational ...
Clinical trials with immune-modulatory and anti-inflammatory therapies ...
Targeted degradation of BRD9 reverses oncogenic gene expression in ...
Frontiers | mRNA vaccines: A novel weapon to control infectious diseases
Binding Mechanism of Inhibitors to BRD4 and BRD9 Decoded by Multiple ...
I-BRD9 82068
广州健康院在BRD9选择性抑制剂研究中获得突破性进展医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Impact of BRD9 inhibitors on cell cycle in RT. Different RT cell lines ...
ACS Medicinal Chemistry Letters | Vol 13, No 10
Targeting Brd4 for cancer therapy: inhibitors and degraders ...
Figure 2 from BRD4 degrader ARV-825 produces long-lasting loss of BRD4 ...
Novel BRD4 Degrader Discovery using DEL Technology
BRD9 inhibitor | BI-9564 | opnMe | Boehringer Ingelheim
〖昇發电子〗全新UC3844B 3844 3844B 3844A UC3844A SOP贴片_虎窝淘
cccc-20240111
Ibtisam Jazuli (Ibby) (@ibtisam_ibby) / Twitter
Novel Compounds for Targeted Degradation of BRD9 and Their Use for ...
Birabresib (OTX015) | ≥99%(HPLC) | Selleck | ブロモドメインと末端外 阻害剤
AACR2022年会披露的10个潜在成药分子，含结构和靶点 - 脉脉
Identification and Development of BRD9 Chemical Probes
Joe Reynolds posted on LinkedIn
Frontiers | Targeted therapies for the treatment of soft tissue sarcoma
(CFT-7455)-药物靶点：IKZF1 + IKZF3_在研适应症：多发性骨髓瘤，非霍奇金淋巴瘤_专利_临床_研发
Heterobifunctional degraders efficiently disrupt BRD4 protein. (A ...
